As manufacturers play an active role in the patients’ healthcare journey, the boundaries between manufacturers and healthcare providers/payers are becoming increasingly blurry. The post It Is Time For The Life Sciences Industry To Rethink Its Relationship with HIPAA appeared first on MedCity News.
On July 17, the option went dead for LGBTQ+ youth to access specialized mental health support from the national 988 Suicide & Crisis Lifeline. The Substance Abuse and Mental Health Services Administration said a month earlier that it would no longer “silo” services and would instead “focus on serving all help seekers.” That meant the…
BOGALUSA, La. — Less than a mile from a century-old mill that sustained generations in this small town north of New Orleans, 19-year-old Tajdryn Forbes was shot to death near his mother’s house. She found Forbes face down in the street in August 2023, two weeks before he had planned to move away from the…
Does Medicare Part B increase or decrease the prices of physician-administered drugs relative to physician-administered drugs covered by private insurance? That is the question a paper by Acquatella, Ericson and Starc (2023) aim to answer. Before we answer that question, we first need to understand how Part B works, how physicians are reimbursed, and how…
Small businesses are struggling with rising costs and tariffs, but many are still looking to maintain or increase health coverage, according to a recent report from Chase. The post Report: Small Businesses Work to Balance Rising Costs and Health Coverage appeared first on MedCity News.
A new Trilliant Health report reveals vast price variation for identical healthcare services, even for procedures delivered at the exact same facility. Allison Oakes, Trilliant’s chief research officer, urged providers to prove they are delivering true value for the cost and pressed employers to leverage their purchasing power to demand higher-value care. The post Same…
Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease. The post FDA Approval Expands Novo Nordisk’s Wegovy to the…
By MATTHEW HOLT So I am back dealing with Labcorp & Blue Shield of California over the mysterious $34 copay. If you want to catch up go here Over the weekend Labcorp sent me a final due notice on my bill…. the one that they couldn’t tell me about without asking for all the information…
Outcomes are no longer a nice-to-have or a post-hoc justification for care provided. They are a central currency of care in a system that’s shifting faster than ever toward accountability. The post For Rehab Providers Outcomes Are the Strategy: Not Just the Scorecard appeared first on MedCity News.
Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families. The post How Employers Can Build an Effective GLP-1 Strategy appeared first on MedCity News.